CURANEX PHARMACEUTICALS INC (CURX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CURX • US23126K1060

0.3238 USD
-0.01 (-3.34%)
At close: Jan 30, 2026
0.3465 USD
+0.02 (+7.01%)
Pre-Market: 2/2/2026, 7:09:24 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CURX. CURX was compared to 191 industry peers in the Pharmaceuticals industry. CURX has a great financial health rating, but its profitability evaluates not so good. CURX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CURX has reported negative net income.
CURX Yearly Net Income VS EBIT VS OCF VS FCFCURX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -100K -200K -300K -400K -500K

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.45%, CURX is in the better half of the industry, outperforming 65.44% of the companies in the same industry.
  • CURX's Return On Equity of -10.59% is fine compared to the rest of the industry. CURX outperforms 73.30% of its industry peers.
Industry RankSector Rank
ROA -10.45%
ROE -10.59%
ROIC N/A
ROA(3y)-97.88%
ROA(5y)N/A
ROE(3y)-100.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CURX Yearly ROA, ROE, ROICCURX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150

1.3 Margins

  • CURX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CURX Yearly Profit, Operating, Gross MarginsCURX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -20 -40 -60

More info and screens

9

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CURX remains at a similar level compared to 1 year ago.
  • CURX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CURX Yearly Shares OutstandingCURX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
CURX Yearly Total Debt VS Total AssetsCURX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100K 200K 300K 400K 500K

2.2 Solvency

  • CURX has an Altman-Z score of 30.28. This indicates that CURX is financially healthy and has little risk of bankruptcy at the moment.
  • CURX has a Altman-Z score of 30.28. This is amongst the best in the industry. CURX outperforms 92.15% of its industry peers.
  • CURX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 30.28
ROIC/WACCN/A
WACCN/A
CURX Yearly LT Debt VS Equity VS FCFCURX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200K -200K 400K -400K

2.3 Liquidity

  • CURX has a Current Ratio of 77.52. This indicates that CURX is financially healthy and has no problem in meeting its short term obligations.
  • CURX has a Current ratio of 77.52. This is amongst the best in the industry. CURX outperforms 99.48% of its industry peers.
  • CURX has a Quick Ratio of 77.52. This indicates that CURX is financially healthy and has no problem in meeting its short term obligations.
  • CURX has a Quick ratio of 77.52. This is amongst the best in the industry. CURX outperforms 99.48% of its industry peers.
Industry RankSector Rank
Current Ratio 77.52
Quick Ratio 77.52
CURX Yearly Current Assets VS Current LiabilitesCURX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100K 200K 300K 400K 500K

More info and screens

0

3. Growth

3.1 Past

  • CURX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1757.14%.
EPS 1Y (TTM)-1757.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CURX Yearly Revenue VS EstimatesCURX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 5K 10K 15K 20K 25K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CURX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CURX Price Earnings VS Forward Price EarningsCURX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CURX Per share dataCURX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CURX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CURANEX PHARMACEUTICALS INC / CURX FAQ

What is the ChartMill fundamental rating of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CURX.


What is the valuation status of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CURANEX PHARMACEUTICALS INC (CURX). This can be considered as Overvalued.


How profitable is CURANEX PHARMACEUTICALS INC (CURX) stock?

CURANEX PHARMACEUTICALS INC (CURX) has a profitability rating of 1 / 10.